Finance

Lists
DRREDDY:NSE
Dr Reddy's Laboratories Ltd
₹1.207,50
+0,37%
(+4,50) 1D
6 ຕ.ລ., 15 ໂມງ 30 ນາທີ 00 ວິນາທີ GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for DRREDDY...
Open
₹1.207,00
High
₹1.212,70
Low
₹1.195,00
Mkt. cap
1,01 ລ້ານລ້ານ
Avg. vol.
1,79 ລ້ານ
Volume
1,64 ລ້ານ
Dividend
0,66%
Quarterly dividend
₹2,00
Ex-dividend date
10 ກ.ລ. 2026
P/E ratio
31,22
52-wk high
₹1.414,90
52-wk low
₹1.101,00
EPS
₹38,67
Shares outstanding
166,06 ລ້ານ
No. of employees
28 ພັນ
Open
₹1.207,00
High
₹1.212,70
Low
₹1.195,00
Mkt. cap
1,01 ລ້ານລ້ານ
Avg. vol.
1,79 ລ້ານ
Volume
1,64 ລ້ານ
Dividend
0,66%
Quarterly dividend
₹2,00
Ex-dividend date
10 ກ.ລ. 2026
P/E ratio
31,22
52-wk high
₹1.414,90
52-wk low
₹1.101,00
EPS
₹38,67
Shares outstanding
166,06 ລ້ານ
No. of employees
28 ພັນ
News stories
From web sources and news partners
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27,5 ພັນ
Founded1984
HeadquartersHyderabad, ອັນດຣາປະເທດ, ອິນເດຍ
SectorPharmaceutical industry
Last report
22 ກ.ລ. 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
₹5,33 / ₹9,13
-41,60%miss
Revenue / Est. (INR)
80,70 ຕື້ / 81,12 ຕື້
-0,51%miss
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
88,05 ຕື້
87,27 ຕື້
75,16 ຕື້
80,70 ຕື້
Cost of goods sold
39,91 ຕື້
40,46 ຕື້
41,47 ຕື້
43,16 ຕື້
Cost of revenue
39,91 ຕື້
40,46 ຕື້
41,47 ຕື້
43,16 ຕື້
Research and development expenses
6,20 ຕື້
6,15 ຕື້
5,46 ຕື້
5,77 ຕື້
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26,44 ຕື້
26,92 ຕື້
27,76 ຕື້
28,82 ຕື້
Operating expense
31,90 ຕື້
32,48 ຕື້
32,53 ຕື້
34,11 ຕື້
Total operating expenses
71,81 ຕື້
72,94 ຕື້
74,00 ຕື້
77,27 ຕື້
Operating income
16,24 ຕື້
14,33 ຕື້
1,16 ຕື້
3,43 ຕື້
Other non operating income
1,28 ຕື້
570,00 ລ້ານ
512,00 ລ້ານ
-
EBT including unusual items
18,35 ຕື້
15,43 ຕື້
1,99 ຕື້
5,53 ຕື້
EBT excluding unusual items
17,81 ຕື້
15,52 ຕື້
1,82 ຕື້
4,09 ຕື້
Income tax expense
4,08 ຕື້
3,53 ຕື້
-214,00 ລ້ານ
1,18 ຕື້
Effective tax rate
22,24%
22,90%
-10,75%
21,32%
Other operating expenses
-740,00 ລ້ານ
-591,00 ລ້ານ
-693,00 ລ້ານ
-477,00 ລ້ານ
Net income
14,37 ຕື້
12,10 ຕື້
2,20 ຕື້
4,44 ຕື້
Net profit margin
16,32%
13,86%
2,93%
5,50%
Earnings per share
17,87
14,77
5,74
5,33
Interest and investment income
912,00 ລ້ານ
796,00 ລ້ານ
890,00 ລ້ານ
999,00 ລ້ານ
Interest expense
-907,00 ລ້ານ
-944,00 ລ້ານ
-1,06 ຕື້
-1,26 ຕື້
Net interest expenses
5,00 ລ້ານ
-148,00 ລ້ານ
-167,00 ລ້ານ
-256,00 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
21,29 ຕື້
19,54 ຕື້
5,03 ຕື້
8,80 ຕື້
Gain or loss from assets sale
-308,00 ລ້ານ
-179,00 ລ້ານ
-2,10 ຕື້
-368,00 ລ້ານ
AI content may include mistakes. Learn more
ແອັບຂອງ Google